The Bull Rankings scorecard — our quality-growth score is 72.8 / 100, built from three pillars scored 0–100: Quality 78, Growth 80, Value 62 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 16% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
LeMaitre Vascular’s current price reflects a company that is already priced for growth but still offers a margin cushion that most peers lack. The Bull Rankings model gives it a quality‑growth score of 72.8/100, with Growth at 80 and Value at 62. The strongest pillar—Growth—anchors the case: revenue is up 11.8% YoY and free cash flow sits at $74 m. The P/E of 27.9 sits near the healthcare median, so the market isn’t overpaying for the upside. The model’s signal that the company is raising its dividend and enjoys durable high returns further sweetens the offer. In short, LMAT is a growth play that still trades on the cheap side of its sector, making today’s price an attractive entry point.
What the business actually is
LeMaitre Vascular manufactures and markets a portfolio of vascular surgery devices. Its core products are allografts—cryopreserved human tissue grafts used in vascular reconstruction and cardiac repair—alongside embolectomy and thrombectomy catheters for clot removal, occlusion catheters that temporarily block blood flow, and perfusion catheters that deliver fluids into the vasculature. The company also offers human cadaver tissue cryopreservation services. These products serve surgeons in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, positioning LeMaitre as a niche supplier in a high‑skill, high‑margin market.
Why it can (and does) keep compounding
Margins are a clear moat. A profit margin of 25% and ROE of 15.6% demonstrate efficient use of capital. The company’s debt‑to‑equity of 0.45 keeps leverage manageable, while a beta of 0.47 indicates low volatility relative to the market. The durable high‑return signal from the model is backed by the fact that free cash flow is already $74 m—a sizable cushion that can fund R&D, acquisitions, or shareholder returns without sacrificing growth. Competing in a field that requires rigorous regulatory approval and specialized manufacturing, LeMaitre’s established supply chain and cryopreservation expertise create a barrier that new entrants would find difficult to replicate quickly.
The valuation question
The P/E of 27.9 is near the healthcare median, so the price is not inflated by a premium multiple. However, the reverse‑DCF implied growth—about 16% a year in year 1, tapering to 4% by year 10—is only slightly above the current revenue growth of 11.8%. This alignment suggests that the market is pricing in a modest acceleration but not a dramatic surge. The implied growth is realistic; it does not overstate the company’s trajectory. The analyst consensus 1‑year target of $107 sits well above the current $79.64, implying that the market still sees room for upside, but the valuation remains anchored to a near‑median P/E and a conservative growth outlook.
The bear case
The softest pillar in the model is Value at 62. While not weak, it signals that the stock is not the cheapest in its sector. A potential downside is that the company’s PEG ratio of 2.09 exceeds the ideal of 1 for a growth play, hinting that the market may be overestimating future earnings growth. If revenue growth stalls below 11.8% or if free cash flow shrinks, the implied 16% growth in year 1 would become unrealistic, eroding the valuation cushion.
What would change our mind
- Revenue growth falling below 10% YoY would make the implied 16% growth appear overly optimistic, weakening the case.
- Free cash flow dipping below $70 m would signal tightening margins and reduce the ability to fund dividends or buybacks.
- A rise in the PEG ratio above 2.5 would suggest the market is pricing in too much future earnings growth, turning the value pillar into a genuine weakness.
If any of these thresholds are breached, the thesis would shift from a compelling growth play to a more cautious stance.